Using two mouse models of RD with different etiologies and rates of retinal degeneration, along with two therapeutic approaches (targeting TRIB3 levels via pharmacological intervention and TRIB3 pseudokinase activity via CPP delivery to the retina), we delayed the onset of retinal degeneration. This evidence concerns the gene TRIB3 and retinal degeneration.